Home > Boards > US OTC > Medical - Equipment >

Repro-Med Systems (REPR)

Add REPR Price Alert      Hide Sticky   Hide Intro
Search This Board: 
Last Post: 2/20/2018 6:43:05 PM - Followers: 75 - Board type: Free - Posts Today: 0

Repro-Med Systems, Inc. (dba RMS Medical Products) engages in the design, manufacture, and marketing of proprietary medical devices primarily for emergency medical applications and ambulatory infusion therapy. It offers the FREEDOM60, an infusion system that enables administration of primary immune deficiency by injecting immune globulin under the skin for the home health care industry and patient emergency transportation. The company's FREEDOM60 is also used for treating thalissemia with the drug desferal; for pain control, primarily post-operative epidural pain administration; and for chemotherapy in Europe. Repro-Med also manufactures the FREEDOM60-FM, which contains an electronic flow monitor system that provides occlusion and end of infusion alarm for nursing homes, hospitals, and pediatric ambulatory applications; and the RES-Q-VAC Emergency Airway Suction System, a hand-operated suction device that removes fluids from a patient's airway by attaching the RES-Q-VAC pump to various proprietary sterile and non-sterile single-use catheters sized for adult and pediatric suctioning. In addition, the company offers DENTAL-EVAC for emergency back up suction during a procedure to oral surgeons; and RES-Q-VAC for military situations, such as exposure to chemical weapons of mass destruction. Repro-Med sells its products directly, as well as through a network of domestic and international distributors, and medical device distributors.

Web Site

Main Products

Historical Financials

Quarter    Q1'07(May)    Q2'07(Aug)    Q3'07(Nov)    Q4'07(Feb)     Q1'08(May)    Q2'08(Aug)    Q3'08(Nov)    Q4'08(Feb)    Q1'09(May)   Q2'09(Aug)
Revenue $347,725 $416,009 $457,991 $512,855 $397,417 $605,946 $620,879 $723,436 $699,976 $936,495
Net Income -$207,314 -$89,149 -$67,695 $29,389 -$178,520 $54,367 $61,359 $55,292 $64,784 $275,529

Press Releases
06/11/2007 Higher Medicare Reimbursment for Freedom60 Syringe Infusion Pump -
08/22/2007 Medicare Clarification Reimbursing the Freedom60 with Subcutaneous Immune Globulin - Interview - Required Listening
some tidbits from the interview:

Investment Thesis
1. The company has been hiring like crazy since the middle of last year. This rapid hiring indicates that business is going quite well. Also, I believe that much of this growth has yet to hit the bottom line. As of Feb 2007 they had 17 employees which makes the evidence in the links below look quite bullish.

Picture of hiring sign on building -
Local DD of international expansion and radio advertising -
Currently available positions -
Bookkeeper / Purchasing Associate 4/24/08 -
Customer coordinator posting 10/02/07 -
Assembler hiring posting 08/30/07 -
Assembler hiring posting 7/24/07 -

2. Freedom60 sales have been growing rapidly and I believe will continue to grow rapidly. Here is why:
a. The Freedom60 pump is the most popular pump used for subcutaneous administration of immunoglobulin (SCIG) according to my conversation with CSL Behring who is the maker of the drug used for SCIG. I also verified this with a nurse. The Freedom60 pump is also the least expensive.
b. Vivaglobin® is the first and only immunoglobulin FDA-approved for subcutaneous administration (SCIG). Vivaglobin sales are increasing rapidly according to CSL's financial report.
c. The Freedom60 is the only device approved by Medicare for in-home SCIG treatment. This point was just clarified in August of last year. Also, Medicare reimbursement for the Freedom60 was increased 20 fold in June of 2007.
d. The FREEDOM60 is superior to other pumps for SCIG. Here is what the company says about this in the 10-K: "We have surmised and have recently confirmed anecdotally that the Freedom60 system because of its constant safe pressure design is the ideal technology to infuse this medication regardless of cost. IgG is quite viscous, and the Freedom60 appears to adjust automatically to patient tissue saturation, preventing complications at the administration sites which include pain, swelling, redness and possible tissue damage. Competitive electronic devices, which are also used for this indication, can deliver higher and quite possibly harmful pressures, and will reach occlusion pressures, which will frequently cause the electronic pumps to shut down prior to completing the drug delivery."
e. The most pervasive treatment for Primary Immunity Deficiency right now is IVIG (intravenous). People are switching to SCIG because:
- It is more convenient.
- It costs less.
- There are less adverse reactions.
- Because treatment is generally done weekly instead of monthly the immunity level remains more constant which should help keep the patient more healthy.
f. The company made bullish statements about growing Freedom60 sales in the last 10-Q.
g. According to the immune deficiency organization ( there are more SGIG drugs that are going through trials right now. This should further increase demand for SCIG treatment and Freedom60 sales.

3. They have high gross margins. Last quarter they were 64%. This means that any additional sales rapidly increase earnings.

4. They get a big recurring revenue stream from each Freedom60 that they sell. Annual sales for supplies for the Freedom60 cost on average $252/unit. The list price for the Freedom60 is $399. The revenue information that they put in the 10-K regarding disposable sales indicates that they are thinking big. See the following post for more info:

5. Growing medical businesses are recession proof. I really like businesses like that right now.

More headquarters pics: (11 total)

Current Price
Bid Ask Day's Range
  • 1D
  • 1M
  • 2M
  • 3M
  • 6M
  • 1Y
  • 2Y
  • 3Y
  • 5Y
REPR News: Statement of Changes in Beneficial Ownership (4) 03/16/2018 05:46:16 PM
REPR News: Amended Statement of Beneficial Ownership (sc 13d/a) 03/16/2018 04:47:15 PM
REPR News: Proxy Statement (definitive) (def 14a) 03/13/2018 11:21:23 AM
REPR News: Annual Transition Report (10-kt) 03/05/2018 04:45:43 PM
REPR News: Statement of Changes in Beneficial Ownership (4) 03/02/2018 06:52:47 PM
PlusOneCoin Top Posts
No plusone'd posts yet. Be the first!
#2144   Truckin' got my chips cashed in blue_skies 02/20/18 06:43:04 PM
#2143   Mike King is the owner of Princeton research blue_skies 02/15/18 01:22:08 PM
#2142   I don't know who Mike King is. mrholty 02/15/18 09:39:09 AM
#2141   There is someone on the buy side the blue_skies 02/14/18 03:54:43 PM
#2140   I do not like the format of the blue_skies 02/14/18 03:51:59 PM
#2139   absolutely agree on where and what the upside mrholty 02/14/18 03:38:30 PM
#2138   The non destructive testing, which was implemented in blue_skies 02/14/18 12:15:23 PM
#2137   agreed with most of what you said. blue_skies 02/14/18 11:52:52 AM
#2136   Revs were up 44% mrholty 02/14/18 10:55:07 AM
#2135   earnings announcement blue_skies 02/13/18 07:24:17 PM
#2134   Maybe they will not be owe taxes until blue_skies 01/11/18 05:30:59 PM
#2133   Now that I have looked at the filings, bigpike 01/09/18 08:59:02 PM
#2132   If you look at the filings carefully, those bigpike 01/04/18 02:18:40 PM
#2131   What I find peculiar is the number of blue_skies 01/04/18 11:54:13 AM
#2130   Wow.... Owned this stock for many years something erpy 12/31/17 07:34:53 PM
#2129   Good volume on a traditionally slow day with blue_skies 12/22/17 02:56:59 PM
#2128 shanak10 12/21/17 01:02:16 PM
#2127   The board of director member, Joe Manko of blue_skies 12/17/17 04:34:15 PM
#2126   Yes to both parts. blue_skies 12/12/17 08:40:54 AM
#2125   Blue, Do you see REPR as a buy out erpy 12/12/17 06:45:14 AM
#2124   REPR is introducing their infusion system to big blue_skies 12/11/17 10:04:11 AM
#2123   Your reaction was my initial reaction. blue_skies 12/08/17 06:01:21 PM
#2122   anytime an officer suddenly quits his post before budge 12/08/17 05:14:24 PM
#2121   I agree the departure does, at first glance blue_skies 12/08/17 04:24:20 PM
#2120   I agree the departure does, at first glance blue_skies 12/08/17 04:24:18 PM
#2119 More purchases, VERY IN erpy 12/07/17 07:45:14 PM
#2118   Thank you for the link SHANAK10 !!!... erpy 12/04/17 09:29:50 PM
#2117 shanak10 12/04/17 08:20:53 PM
#2116   The slow steady upward pressure continues.. Find erpy 12/04/17 08:09:48 PM
#2115   OOOOOOPPPPPS!!!! mispushed the 'F' button. budge 11/28/17 09:46:18 AM
#2114   COO not CFO? bigpike 11/27/17 09:52:51 PM
#2113   I am somewhat concerned by the abrupt departure budge 11/27/17 05:14:18 PM
#2112   they are now licensing tech to big pharma budge 11/27/17 05:12:25 PM
#2111   What is the story with HALO? MWM 11/27/17 01:37:00 PM
#2110   HALO may have something to do with it. budge 11/27/17 11:59:23 AM
#2109   I wonder what is going on... MWM 11/24/17 10:21:50 AM
#2108   Still no one watching this slow and continuous erpy 11/24/17 10:17:32 AM
#2107   Wow glad you posted! I used to own MWM 11/19/17 02:32:57 PM
#2106   Is there any one still following this stock... erpy 11/17/17 04:21:39 PM
#2105   Another message board said their was a FINRA fwentz 04/28/17 03:57:52 PM
#2104   Any reason for the trading halt this morning? fwentz 04/28/17 03:29:40 PM
#2103   Anyone have an update on REPR? curve 09/01/16 06:27:24 PM
#2101   10k out. I wonder what this was bigpike 05/13/16 01:00:12 PM
#2100   Fear the REPR. willlbone 03/09/16 01:53:50 PM
#2099   Think this was a Bowser Report pick some BooDog 01/04/16 07:46:16 AM
#2098   TOO GOOD TO BE TRUE Roy London 01/03/16 01:53:58 PM
#2097   REPR acting better. Presently at .48. curve 12/30/15 09:35:22 AM
#2096   Medical Stock News REPR 4thQuadrant 09/04/15 12:50:40 PM
#2095   Updates anyone? Any insights on REPR? curve 06/12/15 11:50:38 AM
#2094   Those are very reasonable thoughts in my opinion. quilix 01/20/15 08:28:21 PM